初级增强型PspA3 + 2粘膜疫苗保护食蟹猴免受肺炎球菌气管内攻击。

Chieko Yokota, Kosuke Fujimoto, Natsuko Yamakawa, Masamitsu Kono, Daichi Miyaoka, Masaki Shimohigoshi, Miho Uematsu, Miki Watanabe, Yukari Kamei, Akira Sugimoto, Natsuko Kawasaki, Takato Yabuno, Tomotaka Okamura, Eisuke Kuroda, Shigeto Hamaguchi, Shintaro Sato, Muneki Hotomi, Yukihiro Akeda, Ken J Ishii, Yasuhiro Yasutomi, Kishiko Sunami, Satoshi Uematsu
{"title":"初级增强型PspA3 + 2粘膜疫苗保护食蟹猴免受肺炎球菌气管内攻击。","authors":"Chieko Yokota, Kosuke Fujimoto, Natsuko Yamakawa, Masamitsu Kono, Daichi Miyaoka, Masaki Shimohigoshi, Miho Uematsu, Miki Watanabe, Yukari Kamei, Akira Sugimoto, Natsuko Kawasaki, Takato Yabuno, Tomotaka Okamura, Eisuke Kuroda, Shigeto Hamaguchi, Shintaro Sato, Muneki Hotomi, Yukihiro Akeda, Ken J Ishii, Yasuhiro Yasutomi, Kishiko Sunami, Satoshi Uematsu","doi":"10.1186/s41232-023-00305-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to induce a broad range of cross-reactivity with clinical isolates and afford cross-protection against pneumococcal challenge in mice. Furthermore, we developed prime-boost-type mucosal vaccines that induce both antigen-specific IgG in serum and antigen-specific IgA in targeted mucosal organs in previous studies. We investigated whether our prime-boost-type immunization with a fusion PspA was effective against pneumococcal infection in mice and cynomolgus macaques.</p><p><strong>Methods: </strong>C57BL/6 mice were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan. Six weeks later, PspA was administered intranasally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some mice were given intranasal Streptococcus pneumoniae and the severity of infection was analyzed. Macaques were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan at week 0 and week 4. Then, 13 or 41 weeks later, PspA was administered intratracheally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some macaques were intranasally administered S. pneumoniae and analyzed for the severity of pneumonia.</p><p><strong>Results: </strong>Serum samples from mice and macaques injected with antigens in combination with CpG oligodeoxynucleotides and/or curdlan contained antigen-specific IgG. Bronchial samples contained antigen-specific IgA after the fusion PspA boosting. This immunization regimen effectively prevented S. pneumoniae infection.</p><p><strong>Conclusions: </strong>Prime-boost-type immunization with a fusion PspA prevented S. pneumoniae infection in mice and macaques.</p>","PeriodicalId":94041,"journal":{"name":"Inflammation and regeneration","volume":"43 1","pages":"55"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647109/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci.\",\"authors\":\"Chieko Yokota, Kosuke Fujimoto, Natsuko Yamakawa, Masamitsu Kono, Daichi Miyaoka, Masaki Shimohigoshi, Miho Uematsu, Miki Watanabe, Yukari Kamei, Akira Sugimoto, Natsuko Kawasaki, Takato Yabuno, Tomotaka Okamura, Eisuke Kuroda, Shigeto Hamaguchi, Shintaro Sato, Muneki Hotomi, Yukihiro Akeda, Ken J Ishii, Yasuhiro Yasutomi, Kishiko Sunami, Satoshi Uematsu\",\"doi\":\"10.1186/s41232-023-00305-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to induce a broad range of cross-reactivity with clinical isolates and afford cross-protection against pneumococcal challenge in mice. Furthermore, we developed prime-boost-type mucosal vaccines that induce both antigen-specific IgG in serum and antigen-specific IgA in targeted mucosal organs in previous studies. We investigated whether our prime-boost-type immunization with a fusion PspA was effective against pneumococcal infection in mice and cynomolgus macaques.</p><p><strong>Methods: </strong>C57BL/6 mice were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan. Six weeks later, PspA was administered intranasally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some mice were given intranasal Streptococcus pneumoniae and the severity of infection was analyzed. Macaques were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan at week 0 and week 4. Then, 13 or 41 weeks later, PspA was administered intratracheally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some macaques were intranasally administered S. pneumoniae and analyzed for the severity of pneumonia.</p><p><strong>Results: </strong>Serum samples from mice and macaques injected with antigens in combination with CpG oligodeoxynucleotides and/or curdlan contained antigen-specific IgG. Bronchial samples contained antigen-specific IgA after the fusion PspA boosting. This immunization regimen effectively prevented S. pneumoniae infection.</p><p><strong>Conclusions: </strong>Prime-boost-type immunization with a fusion PspA prevented S. pneumoniae infection in mice and macaques.</p>\",\"PeriodicalId\":94041,\"journal\":{\"name\":\"Inflammation and regeneration\",\"volume\":\"43 1\",\"pages\":\"55\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647109/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammation and regeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41232-023-00305-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation and regeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41232-023-00305-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:虽然建议接种疫苗以预防侵袭性肺炎球菌疾病,但全球肺炎球菌性肺炎的发病率仍然很高。事实上,没有疫苗对所有肺炎球菌血清型都有效。融合肺炎球菌表面蛋白A (PspA)已被证明与临床分离株产生广泛的交叉反应性,并在小鼠中对肺炎球菌的攻击提供交叉保护。此外,我们在之前的研究中开发了prime-boost型粘膜疫苗,在血清中诱导抗原特异性IgG,在靶向粘膜器官中诱导抗原特异性IgA。我们研究了融合PspA的初始增强型免疫是否对小鼠和食蟹猴的肺炎球菌感染有效。方法:给C57BL/6小鼠肌肉注射PspA联合CpG寡脱氧核苷酸和/或凝血酶。6周后,经鼻给药PspA。采集血液和支气管肺泡灌洗液,测定抗原特异性IgG和IgA滴度。给一些小鼠鼻内注射肺炎链球菌,分析感染的严重程度。在第0周和第4周肌肉注射融合PspA与CpG寡脱氧核苷酸和/或凝血酶。然后,13周或41周后,气管内给予PspA。采集血液和支气管肺泡灌洗液,测定抗原特异性IgG和IgA滴度。一些猕猴鼻内注射肺炎链球菌并分析其肺炎的严重程度。结果:将抗原与CpG寡脱氧核苷酸和/或凝血蛋白联合注射的小鼠和猕猴血清样品中含有抗原特异性IgG。融合PspA后支气管标本中含有抗原特异性IgA。这种免疫方案有效地预防了肺炎链球菌感染。结论:融合PspA的初始增强型免疫可预防小鼠和猕猴肺炎链球菌感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci.

Background: Although vaccination is recommended for protection against invasive pneumococcal disease, the frequency of pneumococcal pneumonia is still high worldwide. In fact, no vaccines are effective for all pneumococcal serotypes. Fusion pneumococcal surface protein A (PspA) has been shown to induce a broad range of cross-reactivity with clinical isolates and afford cross-protection against pneumococcal challenge in mice. Furthermore, we developed prime-boost-type mucosal vaccines that induce both antigen-specific IgG in serum and antigen-specific IgA in targeted mucosal organs in previous studies. We investigated whether our prime-boost-type immunization with a fusion PspA was effective against pneumococcal infection in mice and cynomolgus macaques.

Methods: C57BL/6 mice were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan. Six weeks later, PspA was administered intranasally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some mice were given intranasal Streptococcus pneumoniae and the severity of infection was analyzed. Macaques were intramuscularly injected with fusion PspA combined with CpG oligodeoxynucleotides and/or curdlan at week 0 and week 4. Then, 13 or 41 weeks later, PspA was administered intratracheally. Blood and bronchoalveolar lavage fluid were collected and antigen-specific IgG and IgA titers were measured. Some macaques were intranasally administered S. pneumoniae and analyzed for the severity of pneumonia.

Results: Serum samples from mice and macaques injected with antigens in combination with CpG oligodeoxynucleotides and/or curdlan contained antigen-specific IgG. Bronchial samples contained antigen-specific IgA after the fusion PspA boosting. This immunization regimen effectively prevented S. pneumoniae infection.

Conclusions: Prime-boost-type immunization with a fusion PspA prevented S. pneumoniae infection in mice and macaques.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.00
自引率
0.00%
发文量
0
期刊最新文献
Cell fusion dynamics: mechanisms of multinucleation in osteoclasts and macrophages. Designer immune cells. Macrophage depletion in inflamed rat knees prevents the activation of synovial mesenchymal stem cells by weakening Nampt and Spp1 signaling. The new era for the research on the regulation of microorganism-induced inflammation. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1